WO2000000825A3 - Detection and modulation of cellular immunity to immune privileged antigens - Google Patents

Detection and modulation of cellular immunity to immune privileged antigens Download PDF

Info

Publication number
WO2000000825A3
WO2000000825A3 PCT/US1999/014827 US9914827W WO0000825A3 WO 2000000825 A3 WO2000000825 A3 WO 2000000825A3 US 9914827 W US9914827 W US 9914827W WO 0000825 A3 WO0000825 A3 WO 0000825A3
Authority
WO
WIPO (PCT)
Prior art keywords
detection
modulation
cellular immunity
immune privileged
privileged antigens
Prior art date
Application number
PCT/US1999/014827
Other languages
French (fr)
Other versions
WO2000000825A9 (en
WO2000000825A2 (en
Inventor
Robert B Darnell
Matthew L Albert
Nina Bhardwaj
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Priority to AU48488/99A priority Critical patent/AU4848899A/en
Priority to EP99932105A priority patent/EP1092154A2/en
Priority to JP2000557146A priority patent/JP2004510950A/en
Priority to CA002336382A priority patent/CA2336382A1/en
Publication of WO2000000825A2 publication Critical patent/WO2000000825A2/en
Publication of WO2000000825A3 publication Critical patent/WO2000000825A3/en
Publication of WO2000000825A9 publication Critical patent/WO2000000825A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Diagnostic and therapeutic methods for the detection of paraneoplastic antigen-specific cells, enhancing tumor immunity by increasing the population of cytotoxic T lymphocytes (CTLs), and suppressing cellular immunity to treat the paraneoplastic syndrome.
PCT/US1999/014827 1998-06-30 1999-06-30 Detection and modulation of cellular immunity to immune privileged antigens WO2000000825A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU48488/99A AU4848899A (en) 1998-06-30 1999-06-30 Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens
EP99932105A EP1092154A2 (en) 1998-06-30 1999-06-30 Detection and modulation of cellular immunity to immune privileged antigens
JP2000557146A JP2004510950A (en) 1998-06-30 1999-06-30 Methods and Agents for Detection and Modulation of Cellular Immunity to Immunoimmune Antigens
CA002336382A CA2336382A1 (en) 1998-06-30 1999-06-30 Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10797898A 1998-06-30 1998-06-30
US09/107,978 1998-06-30

Publications (3)

Publication Number Publication Date
WO2000000825A2 WO2000000825A2 (en) 2000-01-06
WO2000000825A3 true WO2000000825A3 (en) 2000-02-10
WO2000000825A9 WO2000000825A9 (en) 2000-05-25

Family

ID=22319532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/014827 WO2000000825A2 (en) 1998-06-30 1999-06-30 Detection and modulation of cellular immunity to immune privileged antigens

Country Status (4)

Country Link
JP (1) JP2004510950A (en)
AU (1) AU4848899A (en)
CA (1) CA2336382A1 (en)
WO (1) WO2000000825A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1092154A2 (en) 1998-06-30 2001-04-18 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
MXPA01011250A (en) * 1999-05-06 2002-08-12 Univ Wake Forest Compositions and methods for identifying antigens which elicit an immune response.
AU2001234784A1 (en) * 2000-02-04 2001-08-14 Bioseek Compositions and methods for reducing autoimmunity
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
EP1734663B1 (en) 2005-06-17 2011-06-15 Fujitsu Limited Multi-hop communication system
US7928190B2 (en) * 2007-07-05 2011-04-19 Darnell Robert B Methods and compositions for tumor vaccination and therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019635A1 (en) * 1991-04-25 1992-11-12 Sloan-Kettering Institute For Cancer Research Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof
WO1993003375A1 (en) * 1991-08-09 1993-02-18 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5753522A (en) * 1991-12-06 1998-05-19 Legacy Good Samaritan Hospital And Medical Center Purified protein for identifying a cancer-associated retinopathy autoantibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019635A1 (en) * 1991-04-25 1992-11-12 Sloan-Kettering Institute For Cancer Research Antigen recognized by antibodies associated with paraneoplastic opsoclonus and methods of use thereof
WO1993003375A1 (en) * 1991-08-09 1993-02-18 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
US5753522A (en) * 1991-12-06 1998-05-19 Legacy Good Samaritan Hospital And Medical Center Purified protein for identifying a cancer-associated retinopathy autoantibody
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALBERT M L ET AL: "Tumor-specific killer cells in paraneoplastic cerebellar degeneration.", NATURE MEDICINE, (1998). VOL. 4, NO. 11, PP. 1321-4. JOURNAL CODE: CG5. ISSN: 1078-8956., Laboratory of Molecular Neuro-Oncology, Rockefeller University, New York, New York 10021-6399, USA., XP002123818 *
GORDON L B ET AL: "Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.", JOURNAL OF IMMUNOLOGY, (1997). VOL. 159, NO. 5, PP. 2399-408. JOURNAL CODE: IFB. ISSN: 0022-1767., Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI 02912, USA., XP002123817 *
MENG, WILSON S. ET AL: "A model of water structure inside the HLA-A2 peptide binding groove", INT. IMMUNOL. (1997), 9(9), 1339-1346, 1997, XP000856268 *
OKANO H J ET AL: "The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.", GENES AND DEVELOPMENT, (1999). VOL. 13, NO. 16, PP. 2087-97. JOURNAL CODE: FN3. ISSN: 0890-9369., Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York 10021 USA., XP002123819 *
WHITCUP S M ET AL: "Recoverin-associated retinopathy: a clinically and immunologically distinctive disease [see comments].", AMERICAN JOURNAL OF OPHTHALMOLOGY, (1998). VOL. 126, NO. 2, PP. 230-7. JOURNAL CODE: 3OQ. ISSN: 0002-9394., National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-1863, USA., XP000856270 *
YANG Y Y ET AL: "The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998). VOL. 95, NO. 22, PP. 13254-9. JOURNAL CODE: PV3. ISSN: 0027-8424., Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, NY 10021, USA., XP002123820 *

Also Published As

Publication number Publication date
JP2004510950A (en) 2004-04-08
AU4848899A (en) 2000-01-17
WO2000000825A9 (en) 2000-05-25
WO2000000825A2 (en) 2000-01-06
CA2336382A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
IL192679A0 (en) Aglyco products and uses thereof
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU4612093A (en) Soluble ligands for CD40
EP0865293A4 (en) Blockade of t lymphocyte down-regulation associated with ctla-4 signaling
EP0921816A4 (en) Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1999002567A3 (en) Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
WO1999002550A8 (en) Ctl epitopes from ebv
CA2033640A1 (en) Vaccines against cancer and infectious diseases
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
NO20001768D0 (en) Virus encapsulation vaccine, method of preparation and use thereof
DE69839273D1 (en) CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENIC CELLS
BR9815761A (en) Vacuum process for the manufacture of siloxane-oxyalkylene copolymers
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
AU1331100A (en) Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
WO2002000653A3 (en) Fused cyclic compounds as modulators of nuclear hormone receptor function
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
WO1998017313A3 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
WO2000000825A3 (en) Detection and modulation of cellular immunity to immune privileged antigens
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
EP1762620A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 50, DESCRIPTION, REPLACED BY A NEW PAGE 50; PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 557146

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2336382

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 48488/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999932105

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999932105

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999932105

Country of ref document: EP